186 related articles for article (PubMed ID: 15626917)
1. Microdissection-based mutational genotyping of serous borderline tumors of the ovary.
Krishnamurti U; Sasatomi E; Swalsky PA; Jones MW; Finkelstein SD
Int J Gynecol Pathol; 2005 Jan; 24(1):56-61. PubMed ID: 15626917
[TBL] [Abstract][Full Text] [Related]
2. Allelotype of papillary serous peritoneal carcinomas.
Cass I; Baldwin RL; Fasylova E; Fields AL; Klinger HP; Runowicz CD; Karlan BY
Gynecol Oncol; 2001 Jul; 82(1):69-76. PubMed ID: 11426964
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
4. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum.
Huang LW; Garrett AP; Schorge JO; Muto MG; Bell DA; Welch WR; Berkowitz RS; Mok SC
Am J Clin Pathol; 2000 Jul; 114(1):93-9. PubMed ID: 10884804
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors.
Byrom J; Mudaliar V; Redman CW; Jones P; Strange RC; Hoban PR
Int J Oncol; 2004 May; 24(5):1271-7. PubMed ID: 15067351
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity in the MXI1 gene is a frequent occurrence in melanoma.
Ariyanayagam-Baksh SM; Baksh FK; Swalsky PA; Finkelstein SD
Mod Pathol; 2003 Oct; 16(10):992-5. PubMed ID: 14559981
[TBL] [Abstract][Full Text] [Related]
7. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
[TBL] [Abstract][Full Text] [Related]
8. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
[TBL] [Abstract][Full Text] [Related]
9. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
10. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.
Dion F; Mes-Masson AM; Seymour RJ; Provencher D; Tonin PN
Oncogene; 2000 Mar; 19(11):1466-72. PubMed ID: 10723138
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
Jones TD; Eble JN; Wang M; MacLennan GT; Delahunt B; Brunelli M; Martignoni G; Lopez-Beltran A; Bonsib SM; Ulbright TM; Zhang S; Nigro K; Cheng L
Clin Cancer Res; 2005 Oct; 11(20):7226-33. PubMed ID: 16243792
[TBL] [Abstract][Full Text] [Related]
12. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
Prat J; De Nictolis M
Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
[TBL] [Abstract][Full Text] [Related]
13. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a region on chromosome 1p in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma.
Herzog TJ; Kowalski LD; Liu H; Arlt M; Swisher E
Gynecol Oncol; 2001 Jul; 82(1):139-42. PubMed ID: 11426975
[TBL] [Abstract][Full Text] [Related]
15. Clonal selection of adenocarcinoma of the lung as determined by loss of heterozygosity.
Dacic S; Finkelstein SD; Yousem SA
Exp Mol Pathol; 2005 Apr; 78(2):135-9. PubMed ID: 15713439
[TBL] [Abstract][Full Text] [Related]
16. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
[TBL] [Abstract][Full Text] [Related]
18. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
19. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
